All In Biotech

Drug Trial Radar · NCT03866187

Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

A first-time-in Human (FTIH), Phase I/II, Randomized, Multi-centric, Single-blind, Controlled Dose-escalation Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GSK Biologicals' HBV Viral Vector Vaccines Given in a Prime-boost Schedule With Sequential or Co-administration of Adjuvanted Proteins Therapeutic Vaccine (GSK3528869A) in Chronic Hepatitis B Patients (18-65 Years Old) Well Controlled Under Nucleo(s)Tide Analogue (NA) Therapy

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 236 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

236

Actual

Start

Mar 28, 2019

Primary completion

Oct 7, 2024

Study completion Oct 7, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.

Conditions

  • Hepatitis B, Chronic

Interventions

  • ChAd155-hIi-HBV low dose formulationBiological

    Participants in group A1 were scheduled to receive one dose of ChAd155-hIi-HBV low dose formulation on Day 1, by intramuscular injection in the deltoid of the non-dominant arm.

  • ChAd155-hIi-HBV high dose formulationBiological

    Participants in groups B1 and B3 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm. Participants in groups C1 and C2 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.

  • HBc-HBs/AS01B-4 low dose formulationBiological

    Participants in group A1 were scheduled to receive two doses of HBc-HBs/AS01B-4 low dose formulation, one on Day 113 and one on Day 169, and participants in group A2 were scheduled to receive four doses of the HBc-HBs/AS01B-4 low dose formulation, one dose each on Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.

  • HBc-HBs/AS01B-4 high dose formulationBiological

    Participants in group B1 were scheduled to receive two doses of HBc-HBs/AS01B-4 high dose formulation, one on Day 113 and one on Day 169; participants in group B2 were scheduled to receive four doses of HBc-HBs/AS01B-4 high dose formulation, one dose each on Days 1, 57, 113 and 169; participants in group C1 were scheduled to receive four co-administered doses of HBc-HBs/AS01B-4 high dose formulation on Days 1, 57, 113 and 169 and participants in group C2 were scheduled to receive two co-administered doses HBc-HBs/AS01B-4 high dose formulation on Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.

  • MVA-HBV low dose formulationBiological

    Participants in group A1 were scheduled to receive one dose of MVA-HBV low dose formulation on Day 57, by intramuscular injection in the deltoid of the non-dominant arm.

  • MVA-HBV high dose formulationBiological

    Participants in groups B1 and B3 were scheduled to receive one dose of MVA-HBV high dose formulation on Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm. Participants in group C1 were scheduled to receive three co-administered doses of the MVA-HBV high dose formulation on Days 57, 113 and 169 and participants in group C2 were scheduled to receive one co-administered dose of the MVA-HBV high dose formulation on Day 169, by intramuscular injection in the deltoid of the dominant arm.

  • PlaceboDrug

    Participants in group A3 were scheduled to receive four doses of placebo, one each on Days 1, 57, 113 and 169 and participants in group B3 were scheduled to receive two doses of placebo one each on Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Participants in group C2 were scheduled to receive two co-administered doses of placebo on Day 1 and two co-administered doses of placebo on Day 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 1Time frame: Within 7 days after vaccination 1 occurring on Day 1
  2. Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 2Time frame: Within 7 days after vaccination 2 occurring on Day 57
  3. Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 3Time frame: Within 7 days after vaccination 3 occurring on Day 113
  4. Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 4Time frame: Within 7 days after vaccination 4 occurring on Day 169
  5. Number of Participants Reporting Any Solicited Systemic Events After Vaccination 1Time frame: Within 7 days after vaccination 1 occurring on Day 1
  6. Number of Participants Reporting Any Solicited Systemic Events After Vaccination 2Time frame: Within 7 days after vaccination 2 occurring on Day 57
  7. Number of Participants Reporting Any Solicited Systemic Events After Vaccination 3Time frame: Within 7 days after vaccination 3 occurring on Day 113
  8. Number of Participants Reporting Any Solicited Systemic Events After Vaccination 4Time frame: Within 7 days after vaccination 4 occurring on Day 169
  9. Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After Vaccination 1Time frame: Within 30 days after vaccination 1 occurring on Day 1
  10. Number of Participants Reporting Any Unsolicited AEs After Vaccination 2Time frame: Within 30 days after vaccination 2 occurring on Day 57
  11. Number of Participants Reporting Any Unsolicited AEs After Vaccination 3Time frame: Within 30 days after vaccination 3 occurring on Day 113
  12. Number of Participants Reporting Any Unsolicited AEs After Vaccination 4Time frame: Within 30 days after vaccination 4 occurring on Day 169
  13. Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 1Time frame: Within 30 days after vaccination 1 occurring on Day 1
  14. Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 2Time frame: Within 30 days after vaccination 2 occurring on Day 57
  15. Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 3Time frame: Within 30 days after vaccination 3 occurring on Day 113
  16. Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 4Time frame: Within 30 days after vaccination 4 occurring on Day 169
  17. Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: From Day 1 until Day 337
  18. Number of Participants Reporting Potential Immune-mediated Diseases (pIMDs)Time frame: From Day 1 until Day 337
  19. Number of Participants Reporting Liver Disease-related (LDR) Adverse Events of Special Interest (AESIs)Time frame: From Day 1 until Day 337
  20. Number of Participants Reporting Hematological AESIsTime frame: From Day 1 until Day 337
  21. Number of Participants Reporting Medically-attended Adverse Events (MAEs)Time frame: From Day 1 until Day 337

Locations

43 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Antwerp, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Clichy, France

  • GSK Investigational Site

    Créteil, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Strasbourg, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Bonn, Germany

  • GSK Investigational Site

    Essen, Germany

  • GSK Investigational Site

    Frankfurt, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Mainz, Germany

  • GSK Investigational Site

    Pokfulam, Hong Kong

  • GSK Investigational Site

    Krakow, Poland

  • GSK Investigational Site

    Łańcut, Poland

  • GSK Investigational Site

    Mysłowice, Poland

  • GSK Investigational Site

    Poznan, Poland

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Córdoba, Spain

  • GSK Investigational Site

    Granada, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Palma de Mallorca, Spain

  • GSK Investigational Site

    Santander, Spain

  • GSK Investigational Site

    Seville, Spain

  • GSK Investigational Site

    TorrejOn Ardoz Madrid, Spain

  • GSK Investigational Site

    Taichung, Taiwan

  • GSK Investigational Site

    Taichung, Taiwan

  • GSK Investigational Site

    Tainan, Taiwan

  • GSK Investigational Site

    Taipei, Taiwan

  • GSK Investigational Site

    Taoyuan, Taiwan

  • GSK Investigational Site

    Bangkok, Thailand

  • GSK Investigational Site

    Chiang Mai, Thailand

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.